Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.007 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1556-1568 ◽

Cited By ~ 354

Author(s):

Julio Rosenstock ◽

Ronald Brazg ◽

Paula J. Andryuk ◽

Kaifeng Lu ◽

Peter Stein

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Parallel Group Study ◽

Parallel Group

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.03.004 ◽

2008 ◽

Vol 30 (3) ◽

pp. 499-512 ◽

Cited By ~ 90

Author(s):

P COVINGTON ◽

R CHRISTOPHER ◽

M DAVENPORT ◽

P FLECK ◽

Q MEKKI ◽

...

Keyword(s):

Type 2 Diabetes ◽

Multiple Dose ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Multiple Dose Study ◽

Dose Study

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis

Primary Care Diabetes ◽

10.1016/j.pcd.2015.09.001 ◽

2016 ◽

Vol 10 (3) ◽

pp. 210-219 ◽

Cited By ~ 12

Author(s):

Huai Heng Loh ◽

Anne Yee ◽

Huai Seng Loh ◽

Norlela Sukor ◽

Nor Azmi Kamaruddin

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Comparative Studies ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Comparison of Safety and Economic Burden of Dipeptidyl Peptidase-4-Inhibitor Versus Sulfonylureas in Type 2 Diabetes Patients Inadequately Controlled with Metformin; A Narrative Review

Indian Journal of Public Health Research & Development ◽

10.37506/ijphrd.v11i7.10232 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Economic Burden ◽

Dipeptidyl Peptidase ◽

Narrative Review ◽

Dipeptidyl Peptidase 4 ◽

Adherence to dipeptidyl peptidase‐4 inhibitor therapy among type 2 diabetes patients with employer‐sponsored health insurance in Japan

Journal of Diabetes Investigation ◽

10.1111/jdi.12474 ◽

2016 ◽

Vol 7 (5) ◽

pp. 737-743 ◽

Cited By ~ 7

Author(s):

Karen Kurtyka ◽

Rie Nishikino ◽

Chie Ito ◽

Kim Brodovicz ◽

Yong Chen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Health Insurance ◽

Dipeptidyl Peptidase ◽

Inhibitor Therapy ◽

Dipeptidyl Peptidase 4 ◽

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-

Diabetes Obesity and Metabolism ◽

10.1111/dom.12866 ◽

2017 ◽

Vol 19 (5) ◽

pp. 635-643 ◽

Cited By ~ 6

Author(s):

Chang Ho Ahn ◽

Kyung Ah Han ◽

Jae Myung Yu ◽

Joo Young Nam ◽

Kyu Jeung Ahn ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

Diabetes Care ◽

10.2337/dc14-1684 ◽

2015 ◽

Vol 38 (2) ◽

pp. e15-e17 ◽

Cited By ~ 27

Author(s):

Markku Laakso ◽

Julio Rosenstock ◽

Per-Henrik Groop ◽

Anthony H. Barnett ◽

Baptist Gallwitz ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Double Blind Clinical Trial